Electroconvulsive Therapy in Clozapine-resistant Schizophrenia

Not Applicable

• Conditions: Schizophrenia; Schizoaffective Disorder

• Registration Number: NCT02159001
• Lead Sponsor: Niuvanniemi Hospital

Brief Summary

Electroconvulsive therapy (ECT) is one of the oldest neuromodulation treatments still used in psychiatry. Only case reports and open label non-randomized studies have been published of ECT in clozapine-resistant schizophrenia patients. The purpose of this trial is to study the efficacy and cognitive effects of add-on ECT treatment (10-course) in schizophrenia patients taking clozapine.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-06
• Study First Submitted: 2014-06-04
• Study First Submitted QC: 2014-06-05
• Study First Posted: 2014-06-09
• Status Verified: 2015-10
• Last Update Submitted: 2015-10-15
• Last Update Posted: 2015-10-16
• Primary Completion: 2017-12
• Study Completion: 2018-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• diagnosis of schizophrenia or schizoaffective disorder
• treatment-resistant to clozapine
• age 18 - 64 years
• capacity and willingness to give informed consent

Exclusion Criteria

• serious somatic illness
• progressive neurological illness, recent brain damage or sequela of serious brain damage
• ECT less than 3 months prior to this trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Positive and Negative Symptom Scale	2 days	Positive and Negative Symptom Scale (PANSS) is assessed two days after ECT course

Trial Locations

Locations (1)

Niuvanniemi Hospital; 🇫🇮 Kuopio, Finland